The overall ratings of 4 Pharmaceuticals stocks are down on Portfolio Grader this week. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Imprimis Pharmaceuticals, Inc. (IMMY) is having a tough week. The company’s rating falls from a C to a D. Imprimis Pharmaceuticals, Inc. is a pharmaceutical company that focuses on the development and commercialization of non-invasive topically delivered medications. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of IMMY stock.

This week, Achaogen, Inc.’s (AKAO) rating worsens to a D from the company’s C rating a week ago. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of AKAO stock.

VIVUS, Inc.’s (VVUS) rating weakens this week, dropping to a F versus last week’s D. VIVUS, Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutic products for large underserved markets. The company also gets F’s in earnings surprise, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of VVUS stock.

Bio-Path Holdings, Inc. (BPTH) experiences a ratings drop this week, going from last week’s D to a F. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of BPTH stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.